Home > Boards > US Listed > Biotechs > Microbot Medical, Inc. (MBOT)

HINGHAM, Mass., April 1, 2020 – Microbot Medical

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
run256 Member Profile
 
Followed By 4
Posts 182
Boards Moderated 0
Alias Born 04/28/14
160x600 placeholder
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 8/18/2021 5:23:46 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 8/18/2021 5:22:33 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/29/2021 7:01:06 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/10/2021 5:31:03 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/10/2021 5:18:36 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/7/2021 7:00:44 AM
Leading Interventional Cardiologist Dr. Giora Weisz Joins Microbot Medical’s Scientific Advisory Board GlobeNewswire Inc. - 6/7/2021 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/4/2021 7:39:10 AM
Microbot Medical Secures Additional Protection for the One & Done Guidewire Technology with another Notice of Patent Allowanc... GlobeNewswire Inc. - 6/4/2021 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/17/2021 3:44:31 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/3/2021 5:01:04 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/22/2021 4:31:13 PM
Amended Annual Report (10-k/a) Edgar (US Regulatory) - 4/14/2021 5:30:53 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 4/7/2021 9:41:39 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/7/2021 9:27:50 AM
Annual Report (10-k) Edgar (US Regulatory) - 3/31/2021 4:17:24 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/9/2021 7:01:19 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/4/2021 7:01:02 AM
Microbot Medical Granted Patent Allowance in Japan; Global Jurisdictions Recognizing Novel ‘One & Done’ Technology GlobeNewswire Inc. - 2/4/2021 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/3/2021 5:16:48 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/27/2021 8:31:35 AM
Microbot Medical Announces Successful Outcome of its Discussions with FDA Regarding Regulation of Self-Cleaning Shunt GlobeNewswire Inc. - 1/27/2021 8:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/21/2021 7:00:49 AM
Microbot Medical Enhances Scientific Advisory Board with World Renowned Interventional Radiologists GlobeNewswire Inc. - 1/21/2021 7:00:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 1/20/2021 6:16:19 AM
run256   Saturday, 04/04/20 05:13:47 AM
Re: None
Post # of 985 
HINGHAM, Mass., April 1, 2020 – Microbot Medical Inc. (Nasdaq: MBOT) announced the appointment of Aileen Stockburger to the Company's Board of Directors, effective April 1, 2020. Ms. Stockburger is an experienced executive and consultant with extensive expertise in strategizing, managing and closing sizable, complex worldwide mergers and acquisitions, licensing agreements and divestitures, as well as expertise in business development, strategic planning and finance.



“We are excited to have Aileen join us and strengthen our leadership team’s core capabilities, as her strategic track record and vast industry network will add tremendous value to the organization”, commented Harel Gadot, CEO, President and Chairman. “Her proven experience in merger and acquisition transactions as well as the formation and execution of strategic collaborations across the industry, will greatly enhance the Company’s ability to achieve its strategic growth objectives.”



During her almost 30 years at Johnson & Johnson, Ms. Stockburger held several business development and finance roles in Medical Devices, Corporate and Consumer. She served as Worldwide Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group’s merger and acquisition activities. While in that role, she played leading and significant roles in over $70 billion worth of transactions, including: Johnson and Johnson’s acquisition of Synthes, as well as Pfizer Consumer HealthCare, Aveeno, BabyCenter, OraPharma, DePuy, DePuy Mitek, Kodak Clinical Diagnostics and Neutrogena. Before joining Johnson & Johnson, Aileen spent three years at PriceWaterhouse Coopers, where she earned her CPA certification. She received her BS and MBA from the Wharton School, University of Pennsylvania



“Throughout my career I have sought out opportunities that allow me to use my specific skills to help effect meaningful change and impact to the healthcare market,” commented Ms. Stockburger. “I have watched Microbot Medical the past few years, albeit from a distance, and my enthusiasm to join the Board at this specific time is due to its progress developing highly advanced and revolutionary robotic systems that will transform the future of healthcare. I believe that my expertise, combined with Microbot’s assets and ambition, will allow us to address new and emerging growth markets.”



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences